Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameChimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)
Drug Alias NameHunan Yongren Medical InnovationZ-CTLs
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionCluster of differentiation 86 inhibitorsCluster of differentiation 80 inhibitorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Cluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHunan Zhaotai Yongren Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHunan Zhaotai Yongren Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A